Ki Sueng Choi

Associate Professor

Icahn School of Medicine at Mount Sinai
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Obsessive–compulsive disorder (OCD) manifests with diverse symptom constellations that likely arise from dysfunction in partially distinct neural circuits. Deep brain stimulation (DBS), paired with high-resolution connectomics, offers a unique window into these pathways in humans. Here, we analyzed clinical outcomes and stimulation sites from 77 treatment-refractory patients with OCD and 39 with Tourette’s syndrome (TS) exhibiting comorbid obsessive–compulsive behaviors (244 electrodes across 15 cohorts and eight targets). Engagement of the previously defined OCD response tract predicted global obsessive-compulsive symptom improvement across heterogeneous targets and diagnoses, spanning both OCD and TS. Beyond broad symptoms, obsessions, compulsions, anxiety, and depression mapped onto distinct yet overlapping subcircuits fragmenting the anterior limb of the internal capsule along a dorsoventral axis. This fine-scale architecture of OCD circuit dysfunction was reproducible across cross-validation schemes and patient subsets. Exploratory analyses identified additional subcircuits for cognitive control and flexibility. Global functional recovery was better explained by combined engagement of multiple symptom-specific rather than a single tract. Collectively, these findings illustrate how invasive neuromodulation can delineate a multi-symptom circuit taxonomy of compulsivity that may guide personalized neuromodulation.

Year:

2025

Recent advances in deep brain stimulation (DBS) of the subcallosal cingulate (SCC) show promise in mitigating the symptoms of treatment-resistant depression (TRD) in humans 1–3 . Monoamines, such as dopamine and serotonin, mediate the effects of pharmacological treatments of depression. However, their roles in recovery following DBS remain elusive, largely due to technical limitations of measuring these neurotransmitters in the living human brain. Here, by leveraging machine learning-enhanced electrochemistry 4–7 , we show that dopamine and serotonin signaling following DBS to the SCC predicted later depressive symptom relief in humans with TRD. We found that both dopamine and serotonin levels increased following subtherapeutic intraoperative SCC stimulation, with each neurotransmitter showing selective responses to distinct decision-making tasks. Furthermore, acute dopamine increases predicted later mood improvements during a social decision-making task, while serotonin enhancement predicted faster responses during a non-social learning task longitudinally. Critically, changes in dopamine and serotonin levels during the social decision-making task jointly predicted depressive symptom remission at 6-month follow-up. These findings illustrate the contribution of both dopamine and serotonin signaling in predicting behavioral improvement and depressive symptom remission in humans with TRD. Such neurochemical plasticity may serve as potential mechanistic biomarkers for SCC DBS mechanism and TRD treatment response. Significance statement Dopamine and serotonin levels increased following acute DBS to the SCC in humans. Acute dopamine and serotonin changes predicted later mood and response speed changes. Sustained TRD recovery was predicted by acute increases in both dopamine and serotonin estimates.

Year:

2025

Deep brain stimulation (DBS) of the subcallosal cingulate cortex (SCC) is a promising intervention for treatment-resistant depression, yet objective biomarkers that track recovery remain limited. This study examined longitudinal changes in stimulation-evoked potentials (SEPs) to characterize how SCC-driven cortical communication evolves during treatment. Ten patients across three SCC-DBS trials underwent high-density EEG recordings at 4 and 24 weeks. SEP features were extracted from source-localized SCC signals and related to clinical outcomes and fractional anisotropy (FA) of midcingulate cingulum. Cortical responses showed a consistent reduction in latency and an increase in magnitude over time, indicating faster and stronger electrocortical signaling with chronic stimulation. Higher baseline midcingulate FA predicted greater latency acceleration, linking SEP timing to white-matter integrity. These findings identify temporal SEP dynamics as candidate mechanistic biomarkers that reflect circuit engagement during SCC-DBS and offer a pathway toward physiology-guided optimization of neuromodulation for depression. Highlights Reduced latency of stimulation evoked potential after 6 months of DBS Larger cortical evoked response to single pulse perturbation after 6 months of DBS Baseline myelin integrity in MCC predicts magnitude of change in EP latency

Year:

2025

Auditory verbal hallucinations (AVH) in treatment-resistant schizophrenia (TR SZ) are often unresponsive to pharmacologic interventions, necessitating novel therapeutic approaches. We report a case of a patient with persistent AVH who underwent deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr). To investigate the neurophysiological effects of SNr stimulation on cortical activity during AVH, we performed intraoperative electrocorticography (ECoG) over the left inferior parietal cortex using a 63-channel grid. Real-time recordings captured episodes of AVH and revealed elevated theta-gamma phase-amplitude coupling (PAC), a marker of aberrant cortical synchronization. DBS intervention resulted in normalization of PAC dynamics, with both average PAC and spatial distribution returning to non-AVH levels. Clinically, SNr DBS was associated with a 64% reduction in AVH frequency. These findings provide the first real-time functional evidence linking SNr activity to cortical oscillatory changes underlying AVH. This case supports the potential of SNr as a novel neuromodulatory target in TR SZ and highlights theta-gamma PAC as a candidate biomarker for mechanistic tracking of AVH symptomatology.

Year:

2025

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet its diagnosis relies on clinical symptoms alone. Using machine learning applied to deeply phenotyped, medication-free participants with MDD, we identified two neuroanatomical dimensions. Dimension 2 (D2), compared to Dimension 1 (D1), was characterized by reductions in grey and white matter and was associated with limited treatment response to both antidepressant and placebo medications. Validation in UK Biobank general population cohort (n = 37,235) confirmed that D2 is characterized by reduced grey and white matter, alongside widespread cognitive impairments, adverse events in both adulthood and childhood, increased self-harm and suicide attempts, a pro-atherogenic lipid profile, and genetic associations with neurodegenerative traits. These findings suggest that D1 and D2 reflect distinct neurobiological mechanisms underlying MDD, with important implications for and treatment outcomes. External validation was demonstrated in a general population-based cohort that delineated mechanisms underlying heterogeneity in MDD, identifying potential biomarkers that could aid in personalising treatment approaches for this debilitating disorder.

Year:

2025

Therapeutic brain stimulation targets are typically designed to treat specific psychiatric or neurological symptoms. 1–4 This approach presents a dilemma when treating patients with comorbidities, atypical symptom profiles, or overlapping symptoms. Identifying targets that modulate groups of behavioral or cognitive symptoms across diagnoses may provide alternative treatment options and outcomes. Here, we use causal brain mapping and clustering methods to identify two distinct brain networks, based on common patterns of connectivity to lesions that selectively modify behaviors and symptoms. Due to the behavioral items in each cluster, we hypothesize that these networks are related to positive and negative affect, respectively. Across ten different datasets of patients receiving transcranial magnetic stimulation (TMS) or deep brain stimulation (DBS), 1,5,6 stimulation site connectivity to each of our two brain networks independently predicted improvement in depressive symptoms. Thus, we defined two networks which are independently and causally involved in depression symptoms.

Year:

2024

Collaborators (50)

Harith Akram

Consultant neurosurgeon and Honorary Associate Professor

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

Vincenzo Fiore

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Benicio N. Frey

McMaster University

CANADA
View details

Joost de Jong

Senior researcher

Maastricht University Medical Centre

NETHERLANDS
View details

Robert Richardson

Director, Functional Neurosurgery

Massachusetts General Hospital

UNITED STATES
View details

Haochang Shou

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Ludvic Zrinzo

Professor of Neurosurgery., Head Unit of Functional Neurosurgery

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

stephan chabardes

Grenoble Alpes University Hospital

FRANCE
View details

Patricio Riva-Posse

Associate Professor

Emory University

UNITED STATES
View details

Andrew McIntosh

Professor of Biological Psychiatry

University of Edinburgh

UNITED KINGDOM
View details

Xiaosi Gu

Associate Professor

University of Texas at Dallas

UNITED STATES
View details

Catherine Harmer

Associate Head of Department

University of Oxford

UNITED KINGDOM
View details

Fidel Vila-Rodriguez

Associate Professor

The University of British Columbia

CANADA
View details

Eileen Joyce

University College London

UNITED KINGDOM
View details

Sameer Sheth

Baylor College of Medicine

UNITED STATES
View details

Susan L Rossell

Swinburne University of Technology

AUSTRALIA
View details

David Castle

University of Tasmania

CANADA
View details

Bryan Strange

Profesor I3

Universidad Politécnica de Madrid

SPAIN
View details

Boadie Dunlop

Professor and Chair

Augusta University Medical College of Georgia

UNITED STATES
View details

Ignacio Saez

Assistant professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Ankur Butala

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Christopher Butson

Associate Professor

University of Utah

UNITED STATES
View details

Chao-Gan Yan

Professor

Tsinghua University

CHINA
View details

Martin Paulus

Laureate Institute for Brain Research

UNITED STATES
View details

Ayaka Kato

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Martijn Figee

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Jonathan Savitz

Associate Professor

University of Tulsa

UNITED STATES
View details

John Deakin

The University of Manchester

UNITED KINGDOM
View details

Thomas Foltynie

University College London

UNITED KINGDOM
View details

Alon Mogilner

Associate Professor (Clinical) of Anesthesiology, Perioperative Care and Pain Medicine and Neurosurgery (Academic)

NYU School of Medicine

UNITED STATES
View details

Rebecca Elliott

The University of Manchester

UNITED KINGDOM
View details

Andrea A. Kühn

Charité - Universitätsmedizin Berlin

GERMANY
View details

Carsten Finke

Charité - Universitätsmedizin Berlin

GERMANY
View details

Michael Bray

Johns Hopkins University

UNITED STATES
View details

Irina Strigo

University of California, San Francisco

UNITED STATES
View details

Christos Ganos

Director

-

GERMANY
View details

Philip Mosley

Commonwealth Scientific and Industrial Research Organisation

AUSTRALIA
View details

Jordan H. Grafman

Professor in Physical Medicine and Rehabilitation, Cognitive Neurology and Alzheimer's Disease Center, Psychiatry and Behavioral Sciences and Weinberg College of Arts and Sciences

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Dan Bang

Associate Professor

Aarhus University

DENMARK
View details

Cynthia Fu

University of East London

UNITED KINGDOM
View details

Michael Okun

Member

Fixel Institute for Neurological Diseases

UNITED STATES
View details

Heather Whalley

Professor of Neuroscience and Mental Health

University of Edinburgh

UNITED KINGDOM
View details

Christopher Rozell

Julian T. Hightower Chair

Georgia Institute of Technology

UNITED STATES
View details

Kara Johnson

Assistant Professor

University of Utah

UNITED STATES
View details

Kenneth Kishida

Professor

Wake Forest School of Medicine

UNITED STATES
View details

Madhukar H. Trivedi

Director

University of Texas Southwestern Medical Center

UNITED STATES
View details

Roland Zahn

King’s College London

UNITED KINGDOM
View details

Leonardo Barbosa

Research Assistant Professor

Fralin Biomedical Research Institute at VTC

UNITED STATES
View details

Melanie Ganz

Associate Professor

University of Copenhagen

DENMARK
View details

Beata Godlewska

University of Oxford

UNITED KINGDOM
View details